← All trials
NCT04047160
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 29, 2019
- Primary completion
- Mar 31, 2021
- Completion date
- Sep 30, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tokyo Metropolitan Komagome HospitalLead sponsor
- Tokyo Metropolitan Komagome HospitalOverall official - principal investigator
- Tokyo Metropolitan Komagome HospitalReponsible party - principal investigator
- Japan Agency for Medical Research and DevelopmentCollaborator
- OHARA Pharmaceutical Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.